4 Results for "

923564-51-6

" in MedChemExpress (MCE) Product Catalog:
Products (4)

4 Results for "923564-51-6" in MCE Product Catalog:

161
161 Publications Verification
Cat. No.: HY-10087
CAS No.: 923564-51-6
Purity:  99.72%
Synonyms: ABT-263
Target:  

Bcl-2 Family

Research Areas:  

Cancer

Navitoclax (ABT-263) is a potent and orally active Bcl-2 family protein inhibitor that binds to multiple anti-apoptotic Bcl-2 family proteins, such as Bcl-xL, Bcl-2 and Bcl-w, with a Ki of less than 1 nM .
loading...
    loading...
Cat. No.: HY-10087R
CAS No.: 923564-51-6
Synonyms: ABT-263 (Standard)
Navitoclax (Standard) (ABT-263 (Standard)) is the analytical standard of Navitoclax (HY-10087). This product is intended for research and analytical applications. Navitoclax (ABT-263 ) is an orally active BH3 mimetic and an inhibitor of Bcl-2, Bcl-xL, and Bcl-w, with a Ki value of <1 nM for each target. Navitoclax triggers endogenous Apoptosis and downregulates the expression of Survivin and TGFβ2. Navitoclax alleviates fibrosis and induces thrombocytopenia. Navitoclax exhibits anticancer activity against a variety of tumors and enhances the efficacy of chemotherapy and radiotherapy. Navitoclax can be used in the research of acute lymphoblastic leukemia, ovarian cancer, and fibrotic diseases .
loading...
    loading...
161
161 Publications Verification
Cat. No.: HY-10087A1
CAS No.: 1093851-28-5
Synonyms: ABT-263 dihydrochloride
Navitoclax dihydrochloride (ABT-263 dihydrochloride) is an orally active BH3 mimetic and an inhibitor of Bcl-2, Bcl-xL, and Bcl-w, with a Ki value of <1 nM for each target. Navitoclax dihydrochloride triggers endogenous Apoptosis and downregulates the expression of Survivin and TGFβ2. Navitoclax dihydrochloride alleviates fibrosis and induces thrombocytopenia. Navitoclax dihydrochloride exhibits anticancer activity against a variety of tumors and enhances the efficacy of chemotherapy and radiotherapy. Navitoclax dihydrochloride can be used in the research of acute lymphoblastic leukemia, ovarian cancer, and fibrotic diseases .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-10087S
CAS No.: 1217620-38-6
Purity:  99.71%
Navitoclax-d8 is the d8-labeled Navitoclax (HY-10087). Navitoclax (ABT-263 ) is an orally active BH3 mimetic and an inhibitor of Bcl-2, Bcl-xL, and Bcl-w, with a Ki value of <1 nM for each target. Navitoclax triggers endogenous Apoptosis and downregulates the expression of Survivin and TGFβ2. Navitoclax alleviates fibrosis and induces thrombocytopenia. Navitoclax exhibits anticancer activity against a variety of tumors and enhances the efficacy of chemotherapy and radiotherapy. Navitoclax can be used in the research of acute lymphoblastic leukemia, ovarian cancer, and fibrotic diseases .
loading...
    loading...